| Literature DB >> 26526943 |
Kenta Masui1, Webster K Cavenee2, Paul S Mischel2.
Abstract
Metabolic reprogramming is a central hallmark of cancer, enabling tumor cells to obtain the macromolecular precursors and energy needed for rapid tumor growth. Understanding how oncogenes coordinate altered signaling with metabolic reprogramming and how cancer cells harness cellular metabolism and its metabolites for their survival may yield new insights into tumor pathogenesis. Here, we review the recently identified central regulatory role for mTORC2, a downstream effector of many cancer-causing mutations, in metabolic reprogramming and cancer drug resistance in glioblastoma. We further consider the emerging concept that mTORC2 may connect genetics with environmental alterations in brain cancer.Entities:
Keywords: drug resistance; glioblastoma; mTORC2; metabolic reprogramming; nutrient
Mesh:
Substances:
Year: 2015 PMID: 26526943 PMCID: PMC4636016 DOI: 10.1111/bpa.12307
Source DB: PubMed Journal: Brain Pathol ISSN: 1015-6305 Impact factor: 6.508